CJC-1295 Without DAC (10mg)

CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and other proteolytic enzymes while preserving full GHRH receptor binding affinity. The 'without DAC' designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which includes a maleimidopropionic acid linker that enables covalent binding to serum albumin. Without the DAC modification, this version has a shorter half-life of approximately 30 minutes, producing a more physiological acute GH pulse rather than the sustained GH elevation seen with the DAC version. CJC-1295 without DAC binds GHRH receptors on pituitary somatotrophs and activates the Gs-cAMP-PKA pathway to stimulate GH release. Its shorter-acting nature produces GH pulses that more closely mimic natural secretion patterns, which some researchers prefer for maintaining physiological feedback regulation. It is frequently studied in combination with ghrelin receptor agonists like ipamorelin for synergistic GH release.

CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and other proteolytic enzymes while preserving full GHRH receptor binding affinity. The 'without DAC' designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which includes a maleimidopropionic acid linker that enables covalent binding to serum albumin. Without the DAC modification, this version has a shorter half-life of approximately 30 minutes, producing a more physiological acute GH pulse rather than the sustained GH elevation seen with the DAC version. CJC-1295 without DAC binds GHRH receptors on pituitary somatotrophs and activates the Gs-cAMP-PKA pathway to stimulate GH release. Its shorter-acting nature produces GH pulses that more closely mimic natural secretion patterns, which some researchers prefer for maintaining physiological feedback regulation. It is frequently studied in combination with ghrelin receptor agonists like ipamorelin for synergistic GH release.

Clinical research used single doses of 15-60 mcg/kg subcutaneously. Research combination protocols with ipamorelin typically study both components simultaneously.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.